bluebird bio, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD; shares in millions, except per-share amounts

	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q4 FY2023 As of Dec 31, 2023	Q1 FY2024 As of Mar 31, 2024	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020
Assets
Current assets:
Cash and cash equivalents
Marketable securities
Accounts receivable
Prepaid expenses
Inventory
Other current assets
Due from factor
Receivables and other current assets
Current assets of discontinued operations
Total current assets

Marketable securities
Property, plant and equipment, net
Goodwill
Intangible assets, net
Operating lease right-of-use assets
Restricted cash and other non-current assets
Non-current assets of discontinued operations
Total assets

Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable
Deferred revenue
Collaboration research advancement, current portion
Due to factor
Accrued expenses and other current liabilities
Operating lease liability, current portion
Current liabilities of discontinued operations
Financing lease liability, current portion
Term loan debt
Total current liabilities

Deferred revenue, net of current portion
Collaboration research advancement, net of current portion
Operating lease liability, net of current portion
Financing lease liability, net of current portion
Other non-current liabilities
Non-current liabilities of discontinued operations
Total liabilities
Stockholders’ equity (deficit):
Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and outstanding at March 31, 2025 and December 31, 2024
Common stock, $0.01 par value, 250,000 shares authorized; 9,790 and 9,728 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders’ equity (deficit)
Total liabilities and stockholders’ equity (deficit)

Common stock, shares authorized (in shares)

Comments